VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according ...
May 19, 2021
0
3